Compare · CI vs GRAL
CI vs GRAL
Side-by-side comparison of The Cigna Group (CI) and GRAIL Inc. (GRAL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and GRAL operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.58B, about 29.7x GRAL ($2.57B).
- Over the past year, CI is down 7.0% and GRAL is up 49.5% - GRAL leads by 56.5 points.
- GRAL has been more active in the news (11 items in the past 4 weeks vs 4 for CI).
- CI has more recent analyst coverage (25 ratings vs 12 for GRAL).
- Company
- The Cigna Group
- GRAIL Inc.
- Price
- $289.49+3.10%
- $59.97-9.94%
- Market cap
- $76.58B
- $2.57B
- 1M return
- +2.69%
- -4.59%
- 1Y return
- -7.00%
- +49.52%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 11
- Recent ratings
- 25
- 12
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest GRAL
- Chief Growth Officer Partridge Andrew John sold $91,070 worth of shares (1,491 units at $61.08), decreasing direct ownership by 0.90% to 163,738 units (SEC Form 4) (withholding obligation)
- Goldman initiated coverage on GRAIL with a new price target
- Chief Executive Officer Ofman Joshua J. was granted 31,055 shares, increasing direct ownership by 8% to 402,271 units (SEC Form 4)
- New insider Partridge Andrew John claimed ownership of 165,229 shares (SEC Form 3)
- Wolfe Research resumed coverage on GRAIL
- GRAIL Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
- GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
- GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference